Cargando…

Tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour‐bearing mice

BACKGROUND: Cancer cachexia is a metabolic wasting syndrome that is strongly associated with a poor prognosis. The initiating factors causing fat and muscle loss are largely unknown. Previously, we found that leukaemia inhibitory factor (LIF) secreted by C26 colon carcinoma cells was responsible for...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandarian, Susan C., Nosacka, Rachel L., Delitto, Andrea E., Judge, Andrew R., Judge, Sarah M., Ganey, John D., Moreira, Jesse D., Jackman, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240747/
https://www.ncbi.nlm.nih.gov/pubmed/30270531
http://dx.doi.org/10.1002/jcsm.12346
_version_ 1783371684645961728
author Kandarian, Susan C.
Nosacka, Rachel L.
Delitto, Andrea E.
Judge, Andrew R.
Judge, Sarah M.
Ganey, John D.
Moreira, Jesse D.
Jackman, Robert W.
author_facet Kandarian, Susan C.
Nosacka, Rachel L.
Delitto, Andrea E.
Judge, Andrew R.
Judge, Sarah M.
Ganey, John D.
Moreira, Jesse D.
Jackman, Robert W.
author_sort Kandarian, Susan C.
collection PubMed
description BACKGROUND: Cancer cachexia is a metabolic wasting syndrome that is strongly associated with a poor prognosis. The initiating factors causing fat and muscle loss are largely unknown. Previously, we found that leukaemia inhibitory factor (LIF) secreted by C26 colon carcinoma cells was responsible for atrophy in treated myotubes. In the present study, we tested whether C26 tumour‐derived LIF is required for cancer cachexia in mice by knockout of Lif in C26 cells. METHODS: A C26 Lif null tumour cell line was made using CRISPR‐Cas9. Measurements of cachexia were compared in mice inoculated with C26 vs. C26(Lif−/−) tumour cells, and atrophy was compared in myotubes treated with medium from C26 vs. C26(Lif−/−) tumour cells. Levels of 25 cytokines/chemokines were compared in serum of mice bearing C26 vs. C26(Lif−/−) tumours and in the medium from these tumour cell lines. RESULTS: At study endpoint, C26 mice showed outward signs of sickness while mice with C26(Lif−/−) tumours appeared healthy. Mice with C26(Lif−/−) tumours showed a 55–75% amelioration of body weight loss, muscle loss, fat loss, and splenomegaly compared with mice with C26 tumours (P < 0.05). The heart was not affected by LIF levels because the loss of cardiac mass was the same in C26 and C26(Lif−/−) tumour‐bearing mice. LIF levels in mouse serum was entirely dependent on secretion from the tumour cells. Serum levels of interleukin‐6 and G‐CSF were increased by 79‐fold and 68‐fold, respectively, in C26 mice but only by five‐fold and two‐fold, respectively, in C26(Lif−/−) mice, suggesting that interleukin‐6 and G‐CSF increases are dependent on tumour‐derived LIF. CONCLUSIONS: This study shows the first use of CRISPR‐Cas9 knockout of a candidate cachexia factor in tumour cells. The results provide direct evidence for LIF as a major cachexia initiating factor for the C26 tumour in vivo. Tumour‐derived LIF was also a regulator of multiple cytokines in C26 tumour cells and in C26 tumour‐bearing mice. The identification of tumour‐derived factors such as LIF that initiate the cachectic process is immediately applicable to the development of therapeutics to treat cachexia. This is a proof of principle for studies that when carried out in human cells, will make possible an understanding of the factors causing cachexia in a patient‐specific manner.
format Online
Article
Text
id pubmed-6240747
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62407472018-12-01 Tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour‐bearing mice Kandarian, Susan C. Nosacka, Rachel L. Delitto, Andrea E. Judge, Andrew R. Judge, Sarah M. Ganey, John D. Moreira, Jesse D. Jackman, Robert W. J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: Cancer cachexia is a metabolic wasting syndrome that is strongly associated with a poor prognosis. The initiating factors causing fat and muscle loss are largely unknown. Previously, we found that leukaemia inhibitory factor (LIF) secreted by C26 colon carcinoma cells was responsible for atrophy in treated myotubes. In the present study, we tested whether C26 tumour‐derived LIF is required for cancer cachexia in mice by knockout of Lif in C26 cells. METHODS: A C26 Lif null tumour cell line was made using CRISPR‐Cas9. Measurements of cachexia were compared in mice inoculated with C26 vs. C26(Lif−/−) tumour cells, and atrophy was compared in myotubes treated with medium from C26 vs. C26(Lif−/−) tumour cells. Levels of 25 cytokines/chemokines were compared in serum of mice bearing C26 vs. C26(Lif−/−) tumours and in the medium from these tumour cell lines. RESULTS: At study endpoint, C26 mice showed outward signs of sickness while mice with C26(Lif−/−) tumours appeared healthy. Mice with C26(Lif−/−) tumours showed a 55–75% amelioration of body weight loss, muscle loss, fat loss, and splenomegaly compared with mice with C26 tumours (P < 0.05). The heart was not affected by LIF levels because the loss of cardiac mass was the same in C26 and C26(Lif−/−) tumour‐bearing mice. LIF levels in mouse serum was entirely dependent on secretion from the tumour cells. Serum levels of interleukin‐6 and G‐CSF were increased by 79‐fold and 68‐fold, respectively, in C26 mice but only by five‐fold and two‐fold, respectively, in C26(Lif−/−) mice, suggesting that interleukin‐6 and G‐CSF increases are dependent on tumour‐derived LIF. CONCLUSIONS: This study shows the first use of CRISPR‐Cas9 knockout of a candidate cachexia factor in tumour cells. The results provide direct evidence for LIF as a major cachexia initiating factor for the C26 tumour in vivo. Tumour‐derived LIF was also a regulator of multiple cytokines in C26 tumour cells and in C26 tumour‐bearing mice. The identification of tumour‐derived factors such as LIF that initiate the cachectic process is immediately applicable to the development of therapeutics to treat cachexia. This is a proof of principle for studies that when carried out in human cells, will make possible an understanding of the factors causing cachexia in a patient‐specific manner. John Wiley and Sons Inc. 2018-09-30 2018-12 /pmc/articles/PMC6240747/ /pubmed/30270531 http://dx.doi.org/10.1002/jcsm.12346 Text en © 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Kandarian, Susan C.
Nosacka, Rachel L.
Delitto, Andrea E.
Judge, Andrew R.
Judge, Sarah M.
Ganey, John D.
Moreira, Jesse D.
Jackman, Robert W.
Tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour‐bearing mice
title Tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour‐bearing mice
title_full Tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour‐bearing mice
title_fullStr Tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour‐bearing mice
title_full_unstemmed Tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour‐bearing mice
title_short Tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour‐bearing mice
title_sort tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in c26 tumour‐bearing mice
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240747/
https://www.ncbi.nlm.nih.gov/pubmed/30270531
http://dx.doi.org/10.1002/jcsm.12346
work_keys_str_mv AT kandariansusanc tumourderivedleukaemiainhibitoryfactorisamajordriverofcancercachexiaandmorbidityinc26tumourbearingmice
AT nosackarachell tumourderivedleukaemiainhibitoryfactorisamajordriverofcancercachexiaandmorbidityinc26tumourbearingmice
AT delittoandreae tumourderivedleukaemiainhibitoryfactorisamajordriverofcancercachexiaandmorbidityinc26tumourbearingmice
AT judgeandrewr tumourderivedleukaemiainhibitoryfactorisamajordriverofcancercachexiaandmorbidityinc26tumourbearingmice
AT judgesarahm tumourderivedleukaemiainhibitoryfactorisamajordriverofcancercachexiaandmorbidityinc26tumourbearingmice
AT ganeyjohnd tumourderivedleukaemiainhibitoryfactorisamajordriverofcancercachexiaandmorbidityinc26tumourbearingmice
AT moreirajessed tumourderivedleukaemiainhibitoryfactorisamajordriverofcancercachexiaandmorbidityinc26tumourbearingmice
AT jackmanrobertw tumourderivedleukaemiainhibitoryfactorisamajordriverofcancercachexiaandmorbidityinc26tumourbearingmice